velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroparesis
Conditions
Gastroparesis
Trial Timeline
Dec 1, 2012 → Feb 1, 2014
NCT ID
NCT01718938About velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo
velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo is a phase 2 stage product being developed by Theravance Biopharma for Gastroparesis. The current trial status is completed. This product is registered under clinical trial identifier NCT01718938. Target conditions include Gastroparesis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01718938 | Phase 2 | Completed |
Competing Products
19 competing products in Gastroparesis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tadalafil + tadalafil + placebo | Eli Lilly | Phase 2 | 52 |
| Granisetron | Kyowa Kirin | Phase 2 | 52 |
| tadalafil | Eli Lilly | Approved | 85 |
| Mosapride + domperidone | Sumitomo Pharma | Approved | 85 |
| Cisapride + Placebo | Johnson & Johnson | Approved | 85 |
| Cisapride + Placebo | Johnson & Johnson | Approved | 85 |
| Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet | AstraZeneca | Phase 2 | 52 |
| Sitagliptin + Placebo | Merck | Phase 1 | 33 |
| Tegaserod | Novartis | Approved | 85 |
| Reglan ODT | UCB | Pre-clinical | 20 |
| Hemin + Albumin | Recordati | Phase 2 | 49 |
| CNSA-001 + Placebo | PTC Therapeutics | Phase 2 | 49 |
| Immediate-release omeprazole + Delayed-release omeprazole | Bausch Health | Approved | 80 |
| Velusetrag + Placebo | Theravance Biopharma | Phase 2 | 47 |
| IW-9179 + Matching Placebo | Ironwood Pharmaceuticals | Phase 2 | 44 |
| VLY-686 (Tradipitant) | Vanda Pharmaceuticals | Phase 2 | 44 |
| Tradipitant | Vanda Pharmaceuticals | Phase 3 | 69 |
| Tradipitant | Vanda Pharmaceuticals | Pre-clinical | 15 |
| Tradipitant + Placebo + Open Label Tradipitant | Vanda Pharmaceuticals | Phase 3 | 69 |